Curasight A/ S Achieves First Milestone under collaboration with Curium Inc.

Curasight Denmark

USD 500.000 payment is the first milestone under the global license and collaboration agreement for the development and commercialization of uTRACE® for use in prostate cancer between Curasight A/S and Curium Inc.Milestone relates to the validation of GMP manufacturing of finished product and illustrates progress in the development plan for uTRACE® PET imaging technologyUnder the agreement signed in 2023 Curasight is eligible to receive up to mUSD 70 in development milestones plus additional commercial milestones and double-digit royalties on sales upon commercializationView original content:https://www.prnewswire.co.uk/news-releases/curasight-as-achieves-first-milestone-under-collaboration-with-curium-inc-302040336.html